Tectonic Positive Phase 1b of TX45 in Pulmonary Hypertension

 

• Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)
• In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days
• TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions (“LVEF”), including LVEF≥50% and LVEF 41-49%

https://www.globenewswire.com/news-release/2025/05/17/3083517/0/en/Tectonic-Therapeutic-Presents-Complete-Results-for-Positive-Phase-1b-Clinical-Trial-of-TX45-in-Patients-with-Group-2-Pulmonary-Hypertension-in-HFpEF-in-Late-Breaking-Presentation-a.html